Abstract: The present invention provides use of a circular RNA with an incomplete double-stranded structure of 16 bp-33 bp in length and/or a promoting agent of the circular RNA with an incomplete double-stranded structure of 16 bp-33 bp in length in preparation of a medicament for treating systemic lupus erythematosus.

Abstract: Programmable guide RNAs (gRNAs) play a central role in the CRISPR revolution sweeping biology and medicine by directing the function of a Cas protein effector to a target gene of choice. To achieve programmable control over regulatory scope, the activity of a conditional guide RNA (cgRNA) depends on the presence or absence of an RNA trigger, allowing for cell-selective regulation of CRISPR/Cas function. Unlike a standard gRNA, a cgRNA is programmable at multiple levels, with the target-binding sequence controlling the target of Cas activity (edit, silence, induce, or bind a gene of choice) and the trigger-binding sequence controlling the scope of Cas activity. cgRNA mechanisms that are allosteric allow for independent design of the target and trigger sequences, providing the flexibility to select the regulatory target and scope independently.

Abstract: The present disclosure relates to engineered penicillin G acylase (PGA) enzymes having improved properties, polynucleotides encoding such enzymes, compositions including the enzymes, and methods of using the enzymes.

Abstract: Nucleic acids comprising multifunctional double-stranded break reporter constructs for stable or transient transfection into a cell, as well as detecting a type of double-stranded break repair mechanism in a cell. Methods for detecting types of double-stranded break repair mechanism in a cell, as well as vectors and cells comprising nucleic acids comprising multifunctional double-stranded break reporter constructs.

Abstract: A CRISPR-Cas3 system was successfully established in a eukaryotic cell.

Abstract: Provided herein are compounds of Formulas (la), (lb), (II) to (VIII), and salts thereof, and methods of making the same. Also provided herein are recombinant proteins useful in the production of compounds disclosed herein, polynucleotides encoding the same, and cells comprising the same.

Abstract: The present disclosure provides compositions and methods for treating, preventing, or inhibiting laminopathies. In one aspect, the disclosure provides nucleic acid constructs and/or vectors comprising a nucleotide sequence encoding lamin A and/or lamin C.

Abstract: The present invention relates to a pharmaceutical composition useful in the prevention and treatment of atrophy or of degeneration of skeletal muscle caused by pathologies or of sarcopenia. The composition includes a combination of molecules that are modulators of the sphingosine-1-phosphate receptors S1PR and one or more pharmaceutically acceptable excipients and/or carriers.

Abstract: The method to produce conditionally apoptotic cells comprises modifying a cell population with a phenotype attributable to human adipose tissue-derived pericytes (AD-PC) expressing anti-tumor TRAIL introducing a sequence coding a conditional suicide gene (CSG).

Abstract: An object of the present invention is to a method for producing a functional substance utilizing a reaction requiring hydrogen, which production method is safe and efficient; and this object is achieved by a method for producing a functional substance utilizing a reaction requiring hydrogen, the method comprising: supplying the hydrogen by culturing of a hydrogen-producing microorganism.

Abstract: Provided herein are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas/guide RNA (gRNA) systems, for the transcriptional repression of Hepatitis B viral (HBV) genes to promote a cellular phenotype that leads to the reduction of HBV infection. In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof in a Hepatitis B viral DNA sequence in cell. In some aspects, the provided systems relate to the transcriptional repression of one or more Hepatitis B viral gene and/or regulatory element thereof. In some aspects, also provided herein are methods and uses related to the provided compositions, for example in repressing Hepatitis B viral replication and expression in connection with Hepatitis B infections.

Abstract: The present disclosure provides methods of improving nuclease-mediated gene targeting frequencies in cells using PFT? or bFGF.

Abstract: A dispensing container and adapter system for use with a planetary mixer is disclosed. The dispensing container has a longitudinal axis and a transverse axis. The dispensing container may include a nozzle and a removable cap to cover the nozzle. The removable cap may have a first width dimension measured along the transverse axis. The dispensing container may include a body having a second width dimension measured along the transverse axis. An adapter may receive the dispensing container. The adapter may include a cavity to receive the removable cap. The cavity may have a cavity width that exceeds the first width dimension. The adapter may also include a recess for receiving a portion of the dispensing container. The recess may extend from the cavity. At least a portion of the recess may have a width dimension smaller than both the first width dimension and the second width dimension.

Abstract: A particulate poly(lactic-co-glycolic) acid (PLGA) is provided. The particulate PLGA comprises a poly(lactic-co-glycolic) acid (PLGA), and has an average volume-based panicle diameter of 80 nm or less and a relative span factor (R.S.F.) satisfying the following formula (1): 0<R.S.F.?1.20??Formula (1) where R.S.F. is defined by (D90?D10/D30, where D90, D50, and D10 respectively represent particle diameters at cumulative rates of 90%, 50%, and 10% by volume based on a cumulative particle size distribution counted from a small-particle side.

Abstract: A collagen-based therapeutic delivery device includes an insoluble synthetic collagen-fibril matrix comprising a polymerization product of soluble oligomeric collagen or a polymerization product of a mixture of soluble oligomeric collagen with one or more type of non-oligomeric soluble collagen molecules, such as, for example, soluble telocollagen and/or soluble atelocollagen, and an active agent dispersed throughout the collagen-fibril matrix or within a portion of the collagen-fibril matrix. A pre-matrix composition includes an aqueous solution including soluble collagen-fibril building blocks and an active agent in the aqueous solution. The soluble collagen-fibril building blocks include soluble oligomeric collagen or a mixture of soluble oligomeric collagen with non-oligomeric soluble collagen molecules. The building blocks are operable to self-assemble into a macromolecular synthetic collagen-fibril matrix in the absence of an exogenous cross-linking agent.

Abstract: According to one or more embodiments, an antifouling material may be produced by forming a nanostructured mold, where a liquid mold precursor is contacted with a textured surface of a nanostructured template, the liquid mold precursor is solidified to the nanostructured template, and the formed nanostructured mold is removed from the nanostructured template. The antifouling material may be formed by contacting a liquid precursor mixture with a textured surface of the nanostructured mold, solidifying the liquid precursor mixture onto the nanostructured mold, and removing the formed antifouling material from the nanostructured mold. The antifouling material may include a nanostructured surface and may further include a toxin.

Abstract: Compositions and formulations for hair treatment are provided herein. Methods for hair treatment, such as methods for preventing or treating hair loss or hair thinning, are also provided herein. The methods and formulations may promote hair growth, hair restoration or hair thickening, or increase hair density or hair growth rate.

Abstract: Methods and kits for treating hair or preventing damage in the relaxing of hair are disclosed herein. Hair that is damaged during a relaxing treatment with hydroxide-containing relaxing agents, can be treated with formulations containing one or more active agents. The active agent formulations can be applied simultaneously with the hair relaxing formulation, or optionally applied immediately following application of the relaxing formulation, to reduce damage and breakage. Use of the active agent formulation along with a relaxing treatment can be used to control the level of curl achieved or retained in the relaxed hair, as compared to the natural amount of curl in the untreated hair.

Abstract: A composition for enhancing bone tissue repair or regeneration is described. The composition includes osteoactivin or an active peptide fragment thereof and a biocompatible material. Osteogenic orthopedic devices including the osteoactivin-containing composition are also described. The devices and compositions can be used in methods for enhancing bone tissue repair or regeneration by contacting a site in need of bone repair or regeneration in a subject with the osteoactivin-containing composition.

Abstract: Compositions, kits, and methods for repairing bonds, for example, disulfide bonds, in hair or on the skin are disclosed. The compositions provide improved conditioning benefit for dry hair or moisturize the skin. The compositions also provide a long lasting moisturized feel and smooth feel to the skin or hair, without feeling greasy. The compositions contain one or more compounds that covalently bind at least two thiol groups in the hair or on the skin. Use of the binding compositions prevents reversion of the repaired bonds to their free thiol state, for at least one week or one month, or more, after a single application of the composition. Improved methods of styling hair, for example permanent hair waving, hair curling, hair coloring or highlighting, and hair straightening, are also provided.